AREV Life Sciences / Absolem JV Receives Extraction Results

VANCOUVER, BC – TheNewswire - December 02, 2021 - AREV Life Sciences Global Corp. AREV AREVF AREV ("AREV") is pleased to announce that it has received the lab test results from the Hericium Erinaceus from its Joint Venture partner Absolem Mushroom Extraction Inc. (a subsidiary of Absolem Health Inc.).

The Company used green solvents suitable for extraction of functional and medicinal fungi and designed a method for the extraction of active compounds known as Hericenones and Erinacines found in lions mane. Lions mane was selected as the initial mushroom to work with due to its legal  status and unique functional properties for mental health, particularly dementia. The method developed can be applied to all other fungi as well as some botanicals where the polarity is suitable. The fruiting body was extracted and came in at over 10% Hericenones. The remaining biomass is useful for an alternative clean form of protein.

The methods and technology we developed result in AREV building on its core competency of extraction and formulation.  Each  "refinement" procedure is being specifically designed for the extraction of the natural substance that is to be ultimately used as an active ingredient for an intended intervention to the particular health condition that is under review. The company is working on extracting Erinacines from the mycelium. Mycelium is a network of fungal threads or hyphae. Think of it as the roots of the fruiting body of the mushroom. Both Absolem and Arev are aware of the numerous additional naturally occurring wild and/or cultivated mushrooms in existence, we are currently expanding our focus accordingly.

Mr. Withrow, stated "These results are very good and we believe we can slightly improve them now that we have a benchmark to work from and have seen the layered components from the extract." He went on to say, "We have local and foreign sources for raw material to extract and will be getting the dry side of the material tested for us as a clean protein source. Mushroom protein is in high demand in a fast growing segment to the sport nutrition market and can be used in the company's future RUTF and RUSF formulations."

For further information, contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For more information visit www.arevlifesciences.com.

On behalf of the Board,

Mike Withrow
CEO & Director

About AREV Life Sciences Global Corp.

AREV is an early-stage life science discovery enterprise dedicated to delivering solutions to public health through discovery, collaborations in the life science industry, and pathogen remediation. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations human nutrition including the late-stage development of a Ready-to-Use Therapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and an Enteral Formula targeting the long-term effects of chronic infection. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and The Biotechnology Innovation Organization (BIO).

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required

under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.  Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements

address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com.   

Copyright (c) 2021 TheNewswire - All rights reserved.